October 30, 2017
Mylan on Monday scored nearly all of the litigation costs it requested in a six-year dispute with The Medicines Co. over a generic version for the blood-thinner Angiomax, with an Illinois federal judge awarding $217,632 after the Federal Circuit found Mylan's generic did not infringe TMC's patents.
October 28, 2014
An Illinois federal court ruled Monday that Mylan Inc.'s proposed generic version of the anticoagulant Angiomax infringed one of The Medicines Co.'s patents for the drug and held that Mylan had failed to prove the patent was unenforceable or invalid.
May 16, 2014
An Illinois federal judge on Thursday partially granted a motion from Mylan Inc. to limit The Medicines Co.'s expert testimony in an upcoming patent trial over Mylan's planned generic version of anticoagulant drug Angiomax.
February 24, 2011
The Medicines Co. filed a patent infringement suit against Mylan Inc. in an Illinois federal court Wednesday in an effort to block the defendant's planned generic version of its anti-coagulant drug Angiomax.